Why the study?
Does prior sulfonylurea therapy worsen in-hospital mortality or infarct size in diabetic patients with acute myocardial infarction?
Does prior sulfonylurea therapy worsen in-hospital mortality or infarct size in diabetic patients with acute myocardial infarction?
In patients with acute myocardial infarction, Type 2 diabetes is associated with higher in-hospital mortality, but prior treatment with sulfonylureas like glibenclamide does not further worsen survival or enlarge infarct size.
Answers are grounded in this paper and cite their sources.
Diabetes raises AMI in-hospital mortality regardless of sulfonylureas; supports observational safety data but leaves causal effects open.
AIMS: Sulfonylureas may interfere with 'ischaemic preconditioning' and worsen the prognosis in diabetic patients with acute myocardial infarction. METHODS AND RESULTS: Three hundred and fifty-seven non-diabetic patients admitted with acute myocardial infarction to one hospital over 6.5 years (72 deaths, in-hospital mortality 20.2%) were compared to 245 Type 2 diabetic patients categorized as having taken sulfonylureas (glibenclamide 7+/-3 mg x day(-1); n = 76, 25 deaths = 32.9%;P = 0.025), not having taken sulfonylureas (n = 89, 29 deaths = 33.0%;P = 0.012), and newly diagnosed as having diabetes (n = 80, 20 deaths = 25.0%). Survival was significantly different (log-rank test: P = 0.03). Increments in creatine kinase and creatine kinase(MB)activity were higher in non-diabetic patients (P<0.01). CONCLUSIONS: In-hospital mortality in Type 2 diabetic patients is higher than in non-diabetic patients suffering acute myocardial infarction regardless of whether or not they had been treated with sulfonylureas. Glibenclamide does not enlarge myocardial necroses.
No takes yet. Share an insight, caveat, or question.
A Klamann (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: